Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis. [PDF]
Antimicrobial Agents and Chemotherapy, 2019 Galactomannan (GM) detection in biological samples has been shown to predict therapeutic response by azoles and polyenes. In a murine invasive pulmonary aspergillosis model, fosmanogepix or posaconazole treatment resulted in an ∼6- to 7-log reduction in ...
Shakti Singh +2 more
exaly +9 more sources
In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris [PDF]
Antimicrobial Agents and Chemotherapy, 2018 Candida auris is an emerging multidrug-resistant yeast that has been responsible for invasive infections associated with high morbidity and mortality. C.
Christopher L. Hager +5 more
core +8 more sources
APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia. [PDF]
Antimicrob Agents Chemother, 2019 non
Viriyakosol S +7 more
europepmc +7 more sources
In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model. [PDF]
Antimicrob Agents Chemother, 2018 APX001 is the prodrug of APX001A, which is a first-in-class small molecule with a unique mechanism of action that inhibits the fungal enzyme Gwt1 in the glycosylphosphatidylinositol (GPI) biosynthesis pathway.
Zhao M +7 more
europepmc +5 more sources
Evaluation of the In Vitro and In Vivo Antifungal Activity of APX001A/APX001 Against Candida auris [PDF]
Open Forum Infectious Diseases, 2017 BACKGROUND: Candida auris, an emerging multidrug-resistant yeast, causes deadly invasive infections with high mortality. C. auris strains often show high MICs to fluconazole and amphotericin B, and some are resistant to all 3 major antifungal classes, limiting treatment options. We tested 16 C.
Christopher Hager +4 more
core +2 more sources
In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. [PDF]
Antimicrob Agents Chemother, 2018 Cryptococcal meningitis (CM), caused primarily by Cryptococcus neoformans , is uniformly fatal if not treated. Treatment options are limited, especially in resource-poor geographical regions, and mortality rates ...
Shaw KJ +12 more
europepmc +4 more sources
678. Galactomannan Is a Biomarker of APX001 (Fosmanogepix) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis [PDF]
Open Forum Infectious Diseases, 2019 Abstract Background Invasive pulmonary aspergillosis (IPA) is a serious fungal infection afflicting immunocompromised patients. Galactomannan (GM) detection in biological samples using the Platelia ELISA has been shown to predict therapy response by azoles, and polyenes.
Ashraf S Ibrahim, Abdullah Alqarihi
exaly +4 more sources
Reason and reality-identifying barriers to patient enrolment for clinical trials in invasive candidiasis. [PDF]
J Antimicrob Chemother, 2022 OBJECTIVES: Enrolment of subjects to clinical trials investigating novel drugs for infectious diseases is an ongoing challenge. In this study, we evaluate factors associated with non-enrolment in treatment trials for invasive candidiasis.
Sprute R +3 more
europepmc +2 more sources
1954. In vivo Efficacy of Delayed Therapy with the Novel Inositol Acyltransferase Inhibitor Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis [PDF]
Open Forum Infectious Diseases, 2019 Abstract Background Candida auris is an emerging pathogen associated with antifungal resistance and high mortality. The novel antifungal manogepix (APX001A) prevents glycosylphosphatidylinositol-anchored protein maturation through inhibition of the inositol acyltransferase Gwt1 enzyme, and has ...
Nathan Paul Wiederhold +2 more
exaly +4 more sources